Recommendations for the use of biologic therapy from the Italian Society for Rheumatology: off-label use.

Monica Todoerti, Nicolo' Pipitone, Marco Matucci-Cerinic, Carlomaurizio Montecucco, Roberto Caporali, Society for Rheumatology Italian Society for Rheumatology

Research output: Contribution to journalArticlepeer-review

Abstract

The advent of biological agents has provided further opportunities to treat resistant or relapsing rheumatic diseases, with robust data for rheumatoid arthritis and spondyloarthritis coming from randomised controlled trials. However there are data also on other rare inflammatory rheumatic diseases even if the evidence available may be heterogeneous and/or controversial. Another challenging scenario is represented by diseases that are not uncommon, but that may present with multiple manifestations and prove resistant to conventional therapies, thus requiring the use of biological agents. To assist physicians in making correct therapeutic choices in such cases, the Italian Society for Rheumatology (SIR) has developed specific recommendations for the use of biological agents in rare disease or for the off-label use of such agents in refractory inflammatory disorders.

Original languageEnglish
JournalClinical and Experimental Rheumatology
Volume29
Issue number3 Suppl 66
Publication statusPublished - May 2011

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Recommendations for the use of biologic therapy from the Italian Society for Rheumatology: off-label use.'. Together they form a unique fingerprint.

Cite this